Mackay Shields LLC’s Acceleron Pharma XLRN Stock Holding History

Mackay Shields LLC’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-9,600	Closed	-$915K	–	1601
2020 Q2	$915K	Sell	9,600 -18,990	-66%	-$1.83M	0.01%	1054
2020 Q1	$2.57M	Sell	28,590 -18,100	-39%	-$1.41M	0.02%	561
2019 Q4	$2.48M	Sell	46,690 -4,600	-9%	-$210K	0.02%	784
2019 Q3	$2.03M	Sell	51,290 -1,600	-3%	-$69.4K	0.01%	897
2019 Q2	$2.17M	Buy	52,890 +36,320	+219%	+$1.5M	0.01%	868
2019 Q1	$772K	Buy	16,570 +100	+0.6%	+$4.39K	0.01%	1070
2018 Q4	$718K	Sell	16,470 -1,713	-9%	-$85.6K	0.01%	1038
2018 Q3	$1.04M	Buy	18,183 +700	+4%	+$34.4K	0.01%	866
2018 Q2	$848K	Buy	17,483 +1,400	+9%	+$51K	0.01%	1000
2018 Q1	$629K	Buy	+16,083	New	+$684K	﹤0.01%	1080

Other funds holding XLRN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Mackay Shields LLC's XLRN Position: Q3 2020 in Review

Mackay Shields LLC sold out of Acceleron Pharma (XLRN) in Q3 2020, closing a stake of 9,600 shares — an estimated $915K sold.

Mackay Shields LLC first reported a position in XLRN in Q1 2018 and held it in 10 quarters. The position peaked at $2.57M in Q1 2020. 238 funds tracked by Wall St. Rank hold XLRN as of Q3 2020.

Mackay Shields LLC reported no remaining Acceleron Pharma position as of Q3 2020 after selling out during the quarter.
Mackay Shields LLC sold 9,600 Acceleron Pharma shares in Q3 2020, an estimated $915K.
Mackay Shields LLC first reported a position in Acceleron Pharma in Q1 2018 and held it in 10 quarters.
Mackay Shields LLC's Acceleron Pharma position peaked at $2.57M in Q1 2020.
238 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2020.

Based on Mackay Shields LLC's 13F filing for Q3 2020, filed 4 Nov 2020.